Search Login Register

rituximab (Mabthera) Summary

Description: mouse/human chimeric mAB; a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma; has immunosuppressive activity

Also Known As: Mabthera; Rituxan; CD20 antibody, rituximab; Genentech brand of rituximab; Hoffmann-La Roche brand of rituximab Show All >>

Networked: 7766 relevant articles (1615 outcomes, 1397 trials/studies) for this Drug

Key Diseases for which rituximab is Relevant

  1. Lymphoma (Lymphomas) : 204 outcomes 204 studies in 1159 results
  2. Non-Hodgkin Lymphoma (Lymphosarcoma) : 154 outcomes 190 studies in 965 results
  3. Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell) : 139 outcomes 153 studies in 732 results
  4. B-Cell Lymphoma (Lymphoma, B Cell) : 122 outcomes 92 studies in 581 results
  5. Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) : 101 outcomes 128 studies in 507 results
Show All >>

Drugs Related to rituximab

  1. Cyclophosphamide (Cytoxan)
  2. Vincristine (Oncovin)
  3. Doxorubicin (Adriamycin)
  4. Prednisone (Sone)
  5. fludarabine
  6. bendamustine
  7. Prednisolone (Predate)
  8. rituximab (Mabthera)
  9. Methotrexate (Mexate)
  10. Antineutrophil Cytoplasmic Antibodies (ANCA)
Show All >>

Therapies Related to rituximab

  1. Drug Therapy (Chemotherapy)
  2. Stem Cell Transplantation
  3. Transplants (Transplant)
  4. Aftercare (After-Treatment)
  5. Immunotherapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.